FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2110901075> ?p ?o ?g. }

• W2110901075 abstract "We investigated the safety and antitumor activity of dalotuzumab, a selective anti-insulin growth factor 1 receptor monoclonal antibody (IGF1R MoAb), plus erlotinib in a sequential phase I/II trial in unselected patients with refractory advanced non-small-cell lung cancer (NSCLC).The phase I trial determined the recommended dose and safety of erlotinib plus dalotuzumab at 5 mg/kg or 10 mg/kg weekly in 20 patients. The phase II trial compared outcomes to erlotinib alone and erlotinib plus dalotuzumab at the mg/kg established in the phase I trial.Erlotinib at 150 mg plus dalotuzumab at 10 mg/kg was safe. The phase II trial included 37 patients in the erlotinib arm and 38 patients in the erlotinib plus dalotuzumab arm. Progression-free survival was 1.6 versus 2.5 months, overall survival was 10.2 and 6.6 months, and the objective response rate was 7.9% and 2.7%, respectively, with no significant differences between the two arms. Grade 3-5 adverse events occurred in 11 (28.9%) versus 13 (35.1%) patients, respectively. The most frequent adverse events were asthenia (36.8% vs. 37.8%), dehydration (5.3% vs. 2.7%), diarrhea (71% vs. 81.1%), hyperglycemia (13.1% vs.18.9%), and skin-related toxicities (92.1% vs. 86.4%).The addition of dalotuzumab to erlotinib did not improve efficacy outcome in patients with refractory advanced NSCLC." @default.
• W2110901075 created "2016-06-24" @default.
• W2110901075 creator A5001587695 @default.
• W2110901075 creator A5009588391 @default.
• W2110901075 creator A5012061864 @default.
• W2110901075 creator A5013513429 @default.
• W2110901075 creator A5028302880 @default.
• W2110901075 creator A5029761367 @default.
• W2110901075 creator A5029871230 @default.
• W2110901075 creator A5033613047 @default.
• W2110901075 creator A5052461112 @default.
• W2110901075 creator A5065954033 @default.
• W2110901075 creator A5072906560 @default.
• W2110901075 creator A5075285660 @default.
• W2110901075 creator A5075347427 @default.
• W2110901075 creator A5087055974 @default.
• W2110901075 date "2014-11-07" @default.
• W2110901075 modified "2023-10-08" @default.
• W2110901075 title "Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial" @default.
• W2110901075 cites W1973210014 @default.
• W2110901075 cites W2006754781 @default.
• W2110901075 cites W2098547168 @default.
• W2110901075 cites W2100189272 @default.
• W2110901075 cites W2121520362 @default.
• W2110901075 cites W2130157823 @default.
• W2110901075 cites W2136137911 @default.
• W2110901075 cites W2138297714 @default.
• W2110901075 cites W2139248078 @default.
• W2110901075 cites W2144722046 @default.
• W2110901075 cites W2152905269 @default.
• W2110901075 cites W2165136032 @default.
• W2110901075 doi "https://doi.org/10.1186/2162-3619-3-26" @default.
• W2110901075 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4237770" @default.
• W2110901075 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25414803" @default.
• W2110901075 hasPublicationYear "2014" @default.
• W2110901075 type Work @default.
• W2110901075 sameAs 2110901075 @default.
• W2110901075 citedByCount "27" @default.
• W2110901075 countsByYear W21109010752015 @default.
• W2110901075 countsByYear W21109010752016 @default.
• W2110901075 countsByYear W21109010752017 @default.
• W2110901075 countsByYear W21109010752018 @default.
• W2110901075 countsByYear W21109010752020 @default.
• W2110901075 countsByYear W21109010752021 @default.
• W2110901075 countsByYear W21109010752022 @default.
• W2110901075 countsByYear W21109010752023 @default.
• W2110901075 crossrefType "journal-article" @default.
• W2110901075 hasAuthorship W2110901075A5001587695 @default.
• W2110901075 hasAuthorship W2110901075A5009588391 @default.
• W2110901075 hasAuthorship W2110901075A5012061864 @default.
• W2110901075 hasAuthorship W2110901075A5013513429 @default.
• W2110901075 hasAuthorship W2110901075A5028302880 @default.
• W2110901075 hasAuthorship W2110901075A5029761367 @default.
• W2110901075 hasAuthorship W2110901075A5029871230 @default.
• W2110901075 hasAuthorship W2110901075A5033613047 @default.
• W2110901075 hasAuthorship W2110901075A5052461112 @default.
• W2110901075 hasAuthorship W2110901075A5065954033 @default.
• W2110901075 hasAuthorship W2110901075A5072906560 @default.
• W2110901075 hasAuthorship W2110901075A5075285660 @default.
• W2110901075 hasAuthorship W2110901075A5075347427 @default.
• W2110901075 hasAuthorship W2110901075A5087055974 @default.
• W2110901075 hasBestOaLocation W21109010751 @default.
• W2110901075 hasConcept C121332964 @default.
• W2110901075 hasConcept C121608353 @default.
• W2110901075 hasConcept C126322002 @default.
• W2110901075 hasConcept C142424586 @default.
• W2110901075 hasConcept C143998085 @default.
• W2110901075 hasConcept C197934379 @default.
• W2110901075 hasConcept C2776256026 @default.
• W2110901075 hasConcept C2778087573 @default.
• W2110901075 hasConcept C2779438470 @default.
• W2110901075 hasConcept C2909325608 @default.
• W2110901075 hasConcept C31760486 @default.
• W2110901075 hasConcept C535046627 @default.
• W2110901075 hasConcept C71924100 @default.
• W2110901075 hasConcept C87355193 @default.
• W2110901075 hasConcept C90924648 @default.
• W2110901075 hasConceptScore W2110901075C121332964 @default.
• W2110901075 hasConceptScore W2110901075C121608353 @default.
• W2110901075 hasConceptScore W2110901075C126322002 @default.
• W2110901075 hasConceptScore W2110901075C142424586 @default.
• W2110901075 hasConceptScore W2110901075C143998085 @default.
• W2110901075 hasConceptScore W2110901075C197934379 @default.
• W2110901075 hasConceptScore W2110901075C2776256026 @default.
• W2110901075 hasConceptScore W2110901075C2778087573 @default.
• W2110901075 hasConceptScore W2110901075C2779438470 @default.
• W2110901075 hasConceptScore W2110901075C2909325608 @default.
• W2110901075 hasConceptScore W2110901075C31760486 @default.
• W2110901075 hasConceptScore W2110901075C535046627 @default.
• W2110901075 hasConceptScore W2110901075C71924100 @default.
• W2110901075 hasConceptScore W2110901075C87355193 @default.
• W2110901075 hasConceptScore W2110901075C90924648 @default.
• W2110901075 hasFunder F4320307776 @default.
• W2110901075 hasIssue "1" @default.
• W2110901075 hasLocation W21109010751 @default.
• W2110901075 hasLocation W21109010752 @default.
• W2110901075 hasLocation W21109010753 @default.
• W2110901075 hasLocation W21109010754 @default.
• W2110901075 hasLocation W21109010755 @default.
• W2110901075 hasLocation W21109010756 @default.

• next